DBV Technologies Logo

DBV Technologies

Developing non-invasive skin patch immunotherapy for severe food allergies like peanut and milk.

DBV | PA

Overview

Corporate Details

ISIN(s):
FR0010417345 (+3 more)
LEI:
969500PVBQFWQKVDMD80
Country:
France
Address:
107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies. The company's core technology is the proprietary Viaskin™ platform, an investigational form of epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to deliver biologically active compounds, such as allergens, to the immune cells of the skin, thereby re-educating the immune system. DBV's development pipeline includes product candidates for common food allergies, with its lead program, Viaskin Peanut (DBV712), in late-stage clinical trials for peanut-allergic patients. Another key program is Viaskin Milk (DBV135) for milk allergies. Founded by pediatricians, the company is dedicated to improving the lives of patients with potentially life-threatening food allergies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-14 15:44
Major Shareholding Notification
Franchissement de seuils
French 266.6 KB
2025-06-20 12:46
Major Shareholding Notification
Franchissement de seuils
French 124.2 KB
2025-06-17 16:58
Major Shareholding Notification
Franchissement de seuils
French 107.2 KB
2025-06-12 22:05
Earnings Release
DBV Technologies to Participate in Upcoming EAACI Congress 2025
English 275.8 KB
2025-06-12 22:05
Regulatory News Service
DBV Technologies participera au prochain congrès EAACI 2025
French 269.7 KB
2025-06-11 22:30
Post-Annual General Meeting Information
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025
French 179.9 KB
2025-06-11 22:30
Declaration of Voting Results & Voting Rights Announcements
DBV Technologies Announces the Voting Results of its 2025 Combined General Meet…
English 179.7 KB
2025-06-04 22:32
Declaration of Voting Results & Voting Rights Announcements
Information Regarding the Total Number of Voting Rights and Total Number of Sha…
English 169.6 KB
2025-06-04 22:32
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total des droits de vote et d’actions composant…
French 150.3 KB
2025-06-03 22:30
Registration Form
DBV Technologies publie un amendement à son Document d’enregistrement universel…
French 178.9 KB
2025-06-03 22:30
Registration Form
DBV Technologies announces the filing of an addendum to the 2024 Universal Regi…
English 171.4 KB
2025-05-15 22:30
Pre-Annual General Meeting Information
Assemblée Générale Mixte du 11 juin 2025
French 173.8 KB
2025-05-15 22:30
Pre-Annual General Meeting Information
Combined General Meeting of June 11, 2025
English 193.4 KB
2025-05-06 22:30
Declaration of Voting Results & Voting Rights Announcements
Information regarding the total number of voting rights and  total number of s…
English 95.0 KB
2025-05-06 22:30
Declaration of Voting Results & Voting Rights Announcements
Information relative au nombre total des droits de vote et d’actions composant…
French 100.7 KB

Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DBV Technologies

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DBV Technologies via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-09 N/A Other Other 2,483,161 7,449,483.00 EUR

Peer Companies

Company Country Ticker View
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766
PCI Biotech Holding Logo
Biopharma firm evaluating its future after discontinuing its core technology development.
Norway PCIB

Talk to a Data Expert

Have a question? We'll get back to you promptly.